Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer

Surgery (United States)

Volumn 157, Issue 5, 2015, Pages 888-898

  Larocca, Christopher J ^a   Han, Joohee ^a   Gavrikova, Tatyana ^b   Armstrong, Leonard ^a,c   Oliveira, Amanda R ^a   Shanley, Ryan ^d   Vickers, Selwyn M ^e   Yamamoto, Masato ^a,d,f   Davydova, Julia ^a,f  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Alabama at Birmingham   (United States)

^c Cambridge Medical Center   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOOXYGENASE 2; ONCOLYTIC ADENOVIRUS; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; SYRIAN HAMSTER; ADENOVIRIDAE; ANIMAL; CARCINOMA; EVALUATION STUDY; EXPERIMENTAL NEOPLASM; FEMALE; HAMSTER; HUMAN; MESOCRICETUS; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CRICETINAE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS;

EID: 84929043772     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.01.006     Document Type: Article

References (45)

1. American Cancer Society Cancer facts & figures 2013 2013 American Cancer Society Atlanta
2. N.B. Merchant, A.A. Parikh, and E.H. Liu Adjuvant chemoradiation therapy for pancreas cancer: who really benefits? Adv Surg 44 2010 149 164
3. K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, J. Ritchey, A.K. Stewart, and D.P. Winchester Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database Cancer 110 2007 738 744
4. L.R. Holsti, K. Mattson, A. Niiranen, C.G. Standertskiold-Nordenstam, S. Stenman, and A. Sovijarvi Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung Int J Radiat Oncol Biol Phys 13 1987 1161 1166
5. S. Wadler, R. Wersto, V. Weinberg, D. Thompson, and E.L. Schwartz Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects Cancer Res 50 1990 5735 5739
6. E.E. Vokes The promise of biochemical modulation in combined modality therapy Semin Oncol 21 1994 29 33
7. A. Ismail, C.J. Van Groeningen, A. Hardcastle, Q. Ren, G.W. Aherne, and F. Geoffroy Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma Mol Pharmacol 53 1998 252 261
8. M.J. Morak, P.M. van Koetsveld, R. Kanaar, L.J. Hofland, and C.H. van Eijck Type I interferons as radiosensitisers for pancreatic cancer Eur J Cancer 47 2011 1938 1945
9. J.H. Ma, E. Patrut, J. Schmidt, H.P. Knaebel, M.W. Buchler, and A. Marten Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma World J Gastroenterol 11 2005 1521 1528
10. K. Hoffmann, S. Mehrle, J. Schmidt, M.W. Buchler, and A. Marten Interferon-alpha restitutes the chemosensitivity in pancreatic cancer Anticancer Res 28 2008 1499 1507
11. G. Antoniou, P. Kountourakis, K. Papadimitriou, V. Vassiliou, and D. Papamichael Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions Cancer Treat Rev 40 2014 78 85
12. Y. Nukui, V.J. Picozzi, and L.W. Traverso Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 179 2000 367 371
13. V.J. Picozzi, R.A. Kozarek, and L.W. Traverso Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 185 2003 476 480
14. J. Schmidt, U. Abel, J. Debus, S. Harig, K. Hoffmann, and T. Herrmann Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma J Clin Oncol 30 2012 4077 4083
15. M. Ohashi, K. Yoshida, M. Kushida, Y. Miura, S. Ohnami, and Y. Ikarashi Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer Br J Cancer 93 2005 441 449
16. E.V. Shashkova, J.F. Spencer, W.S. Wold, and K. Doronin Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus Mol Ther 15 2007 598 607
17. E.V. Shashkova, M.N. Kuppuswamy, W.S. Wold, and K. Doronin Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL Cancer Gene Ther 15 2008 61 72
18. H. Hara, A. Kobayashi, K. Yoshida, M. Ohashi, S. Ohnami, and E. Uchida Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster Cancer Sci 98 2007 455 463
19. W.F. Benedict, Z. Tao, C.S. Kim, X. Zhang, J.H. Zhou, and L. Adam Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein Mol Ther 10 2004 525 532
20. K. Hatanaka, K. Suzuki, Y. Miura, K. Yoshida, S. Ohnami, and Y. Kitade Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer J Gene Med 6 2004 1139 1148
21. L. Armstrong, A. Arrington, J. Han, T. Gavrikova, E. Brown, and M. Yamamoto Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy Am J Surg 204 2012 741 750
22. L. Armstrong, J. Davydova, E. Brown, J. Han, M. Yamamoto, and S.M. Vickers Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy Surgery 152 2012 114 122
23. S.J. Duncan, F.C. Gordon, D.W. Gregory, J.L. McPhie, R. Postlethwaite, and R. White Infection of mouse liver by human adenovirus type 5 J Gen Virol 40 1978 45 61
24. H.S. Ginsberg, L.L. Moldawer, P.B. Sehgal, M. Redington, P.L. Kilian, and R.M. Chanock A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia Proc Natl Acad Sci U S A 88 1991 1651 1655
25. M.A. Thomas, J.F. Spencer, M.C. La Regina, D. Dhar, A.E. Tollefson, and K. Toth Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors Cancer Res 66 2006 1270 1276
26. W.S. Wold, and K. Toth Chapter three-Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds Adv Cancer Res 115 2012 69 92
27. K. Yanagi, M. Onda, and E. Uchida Effect of angiostatin on liver metastasis of pancreatic cancer in hamsters Jpn J Cancer Res 91 2000 723 730
28. J. Davydova, T. Gavrikova, E.J. Brown, X. Luo, D.T. Curiel, and S.M. Vickers In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy Cancer Sci 101 2010 474 481
29. K. Doronin, K. Toth, M. Kuppuswamy, P. Krajcsi, A.E. Tollefson, and W.S. Wold Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus Virology 305 2003 378 387
30. K. Doronin, K. Toth, M. Kuppuswamy, P. Ward, A.E. Tollefson, and W.S. Wold Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J Virol 74 2000 6147 6155
31. J. Davydova, L.P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment Cancer Res 64 2004 4319 4327
32. M. Yamamoto, J. Davydova, M. Wang, G.P. Siegal, V. Krasnykh, and S.M. Vickers Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer Gastroenterology 125 2003 1203 1218
33. H.A. Ono, L.P. Le, J.G. Davydova, T. Gavrikova, and M. Yamamoto Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region Cancer Res 65 2005 10154 10158
34. J.G. Wesseling, P.J. Bosma, V. Krasnykh, E.A. Kashentseva, J.L. Blackwell, and P.N. Reynolds Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors Gene Ther 8 2001 969 976
35. J.K. Kaufmann, and D.M. Nettelbeck Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond Trends Mol Med 18 2012 365 376
36. M. Yamamoto, and D.T. Curiel Current issues and future directions of oncolytic adenoviruses Mol Ther 18 2010 243 250
37. H. Wang, I. Beyer, J. Persson, H. Song, Z. Li, and M. Richter A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses J Virol 86 2012 6286 6302
38. H. Wang, Z.Y. Li, Y. Liu, J. Persson, I. Beyer, and T. Moller Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 Nat Med 17 2011 96 104
39. P.J. Ramirez, S.M. Vickers, H.A. Ono, J. Davydova, K. Takayama, and T.C. Thompson Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model Am J Surg 195 2008 481 490
40. K. Ottolino-Perry, N. Tang, R. Head, C. Ng, R. Arulanandam, and F.A. Angarita Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis Int J Cancer 134 2014 717 730
41. J.G. Wesseling, M. Yamamoto, Y. Adachi, P.J. Bosma, M. van Wijland, and J.L. Blackwell Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma Cancer Gene Ther 8 2001 990 996
42. P.L. Crowell, C.M. Schmidt, M.T. Yip-Schneider, J.J. Savage, D.A. Hertzler 2nd, and W.O. Cummings Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia Neoplasia 8 2006 437 445
43. M. Yamamoto, R. Alemany, Y. Adachi, W.E. Grizzle, and D.T. Curiel Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers Mol Ther 3 2001 385 394
44. J.M. Koeller Biologic response modifiers: the interferon alfa experience Am J Hosp Pharm 46 1989 S11 S15
45. K. Suzuki, K. Aoki, S. Ohnami, K. Yoshida, T. Kazui, and N. Kato Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model Gene Ther 10 2003 765 773